Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Non-Hodgkin Lymphoma: early-phase trial registry
13 of 17 indexed Relapsed Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 13 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Relapsed Non-Hodgkin Lymphoma: 17 US clinical trials tracked, 13 recruiting.
Relapsed Non-Hodgkin Lymphoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Lyell Immunopharma, running 2 of these trials.
Enrollment posture brief
Registry condition relapsed-non-hodgkin-lymphoma
OPEN 13 | RECR 76% | LATE 1 | EARLY 16 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Healthy (Controls) (76% recruiting · 17 trials)
Relapsed Non-Hodgkin Lymphoma lists 13 open slots (76% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Non-Hodgkin Lymphoma is recruiting above its size-band peers.
13 of 17 indexed trials (76.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Relapsed Non-Hodgkin Lymphoma trials is spread across many organizations.
Lyell Immunopharma accounts for 2 of 17 trials (11.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Relapsed Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Relapsed Non-Hodgkin Lymphoma research is mostly interventional.
17 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma
NCT07188558
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma
NCT05826535
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics
NCT06119685
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06839456
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences
NCT04637763
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT06550141
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
NCT06104592
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
SIRPant Immunotherapeutics
NCT05967416
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Rita Assi
NCT06484920
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Lazaros Lekakis
NCT05260957
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma
NCT06343311
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
NCT06544265
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
NCT05828589
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
NCT05621096
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Paolo Caimi, MD
NCT05053659
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
NCT03774654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Non-Hodgkin Lymphoma page
17 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Relapsed Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lyell Immunopharma sponsors the most Relapsed Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Lyell Immunopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Non-Hodgkin Lymphoma condition card totals 17 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.